Literature DB >> 17986877

Office-based laryngeal laser surgery with the 532-nm pulsed-potassium-titanyl-phosphate laser.

Steven M Zeitels1, James A Burns.   

Abstract

PURPOSE OF REVIEW: Office-based laryngeal laser surgery is a recent innovation. It is emerging as a reliable and practical method of treating a number of laryngeal lesions, which is increasingly popular in the US and abroad. The 532-nm pulsed-potassium-titanyl-phosphate laser has become our laser of choice in treating vocal-fold lesions and diseases for a number of transparent and practical reasons. RECENT
FINDINGS: Fiber-based lasers and distal-chip flexible endoscopy have facilitated a new style of surgery. Epithelial diseases such as dysplasia and papillomatosis are well suited for this treatment. Although the initial angiolytic laser used in the larynx was a 585-nm pulsed-dye laser, the solid-state 532-nm pulsed-potassium-titanyl-phosphate laser has been demonstrated to be more effective clinically, more reliable structurally and less expensive.
SUMMARY: Technologies to enhance laryngoscopic imaging and lasers, along with socioeconomic forces, should lead to increasing numbers of laryngeal procedures being done in the office with local anesthesia. The 532-nm pulsed-potassium-titanyl-phosphate laser has emerged thus far as the optimal technology for treating phonatory mucosa although further development is likely.

Entities:  

Mesh:

Year:  2007        PMID: 17986877     DOI: 10.1097/MOO.0b013e3282f1fbb2

Source DB:  PubMed          Journal:  Curr Opin Otolaryngol Head Neck Surg        ISSN: 1068-9508            Impact factor:   2.064


  10 in total

1.  Symptomatic vallecular cysts: diagnosis and management with the KTP laser.

Authors:  Craig H Zalvan; Erin Reilly
Journal:  Eur Arch Otorhinolaryngol       Date:  2016-04-07       Impact factor: 2.503

2.  [Vocal fold scars: pathogenesis, diagnosis, therapy].

Authors:  G Friedrich; M Gugatschka
Journal:  HNO       Date:  2013-02       Impact factor: 1.284

Review 3.  Vocal fold scars: current concepts and future directions. Consensus report of the Phonosurgery Committee of the European Laryngological Society.

Authors:  G Friedrich; F G Dikkers; C Arens; M Remacle; M Hess; A Giovanni; S Duflo; A Hantzakos; V Bachy; M Gugatschka
Journal:  Eur Arch Otorhinolaryngol       Date:  2013-04-21       Impact factor: 2.503

4.  New 445 nm blue laser for laryngeal surgery combines photoangiolytic and cutting properties.

Authors:  Markus M Hess; Susanne Fleischer; Marcel Ernstberger
Journal:  Eur Arch Otorhinolaryngol       Date:  2018-04-19       Impact factor: 2.503

5.  Feasibility and Associated Limitations of Office-Based Laryngeal Surgery Using Carbon Dioxide Lasers.

Authors:  Hao-Chun Hu; Shu-Yi Lin; Yi-Ting Hung; Shyue-Yih Chang
Journal:  JAMA Otolaryngol Head Neck Surg       Date:  2017-05-01       Impact factor: 6.223

Review 6.  Use of lasers in laryngeal surgery.

Authors:  Yan Yan; Aleksandra E Olszewski; Matthew R Hoffman; Peiyun Zhuang; Charles N Ford; Seth H Dailey; Jack J Jiang
Journal:  J Voice       Date:  2009-05-31       Impact factor: 2.009

7.  Outcomes Following Cordotomy by Coblation for Bilateral Vocal Fold Immobility.

Authors:  Michael S Benninger; Roy Xiao; Kyra Osborne; Paul C Bryson
Journal:  JAMA Otolaryngol Head Neck Surg       Date:  2018-02-01       Impact factor: 6.223

8.  [Angiolytic laser applications for the larynx : Phonosurgical concepts for transoral laser microsurgery].

Authors:  S Strieth; J Hagemann; M Hess
Journal:  HNO       Date:  2020-01       Impact factor: 1.284

9.  Endoscopic coblation-assisted and partial arytenoidectomy for infants with idiopathic bilateral vocal cord paralysis.

Authors:  Letian Tan; Chao Chen; Qi Li
Journal:  Medicine (Baltimore)       Date:  2022-01-28       Impact factor: 1.889

10.  Angiolytic laser stripping versus CO2 laser microflap excision for vocal fold leukoplakia: Long-term disease control and voice outcomes.

Authors:  Jae-Yol Lim; Young Min Park; Minsuk Kang; Seung Jin Lee; Kwangha Baek; Jina Na; Hong-Shik Choi
Journal:  PLoS One       Date:  2018-12-31       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.